Table 3.
Multivariable analysis comparing DFS and OS between CD73 expression groups in patients with localized RCC
| DFS | OS | ||||||||
| CD73 expression groups | N | Event (n) | 5-year DFS, % (95% CI) |
Adjusted HR (95% CI)* |
Adjusted P value | Event (n) | 10 year OS, % (95% CI) |
Adjusted HR (95% CI)* | Adjusted P value |
| CD73negative | 82 | 32 | 75 (63 to 83) | Reference | 25 | 64 (51 to 74) | Reference | ||
| CD73low | 12 | 7 | 50 (21 to 74) | 1.22 (0.50 to 2.98) | 0.659 | 5 | 71 (34 to 90) | 0.78 (0.27 to 2.30) | 0.655 |
| CD73high | 13 | 10 | 42 (15 to 67) | 2.72 (1.27 to 5.85) | 0.010 | 9 | 22 (4 to 50) | 2.59 (1.15 to 5.84) | 0.021 |
| CD73high vs CD73low+negative | 2.89 (1.37 to 6.07) | 0.005 | 2.86 (1.30 to 6.29) | 0.009 | |||||
Results in bold indicate statistically significant results
*Adjusted for Fuhrman nuclear grade (G1–2 vs G3–4) and AJCC stage (stage I/II vs III/IV). Multivariable models excluded four patients with unknown grade or stage.
AJCC, American Joint Committee on Cancer; DFS, disease-free survival; OS, overall survival; RCC, renal cell carcinoma.